HEALTH
Industry executives and investment bankers said some of the biggest global drugmakers are scouring for deals in China to replenish drug pipelines and boost their presence in the world's second-biggest pharmaceutical market. Several major deals have already been completed this year, including AstraZeneca's $1.2 billion purchase of China-based cell therapy
Elizabeth Holmes Seeks to Avoid Prison Over Theranos Fraud
Elizabeth Holmes urged a U.S. judge not to send her to prison, as the founder of since-fallen Theranos...
In Online Conference, Experts Discuss Staggering New Heights of Beijing’s Organ Harvesting Crimes
For decades now, Chinese authorities have boasted of their country’s booming transplant industry — which...
McKinsey Reaches Deal With Local US Governments Over Opioid Crisis
(Reuters) — Leading consulting firm McKinsey & Co has agreed to settle claims by hundreds of U.S....
NIH Website Silently Adds Ivermectin as ‘Being evaluated to treat COVID-19’
As of Friday, Oct. 21, social media users have noticed that the antiparasitic drug Ivermectin has been...
Britons Turn to ‘Warm Banks’ Amid Political Turmoil and Worsening Inflation
LONDON (Reuters) — As winter approaches and temperatures dip, charities and local authorities across...
Long COVID at 12 Months Persists at 18 Months: Study
(Reuters) — Most patients with COVID-19 who have lingering symptoms at 12 months are likely to still...
SY Aesthetics: Where Traditional Healing Meets Modern Western Medicine
By pioneering a holistic approach into the world of cosmetic medicine, a leading group of plastic surgeons...
10 Tips for Healthy Aging From Doctors
How can patients actively facilitate healthy aging, according to doctors? The American Medical Association...
The FDA’s New Definition of ‘Healthy’
Poor nutrition is one of the key lifestyle risks for chronic disease, along with tobacco use, alcohol...